NCT04576000View on ClinicalTrials.gov

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis

TerminatedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

December 15, 2020

Study Completion Date

December 2, 2021

Conditions
Ulcerative Colitis
Interventions
DRUG

Janus Kinase Inhibitor

Janus Kinase inhibitor induction therapy will be administered according to Standard Of Care (SOC)

Trial Locations (1)

1105 AZ

Amsterdam Medical Center, IBD Center, Amsterdam

Sponsors

Lead Sponsor

Alimentiv Inc.
All Listed Sponsors
collaborator

Alimentiv Translational Research Consortium

UNKNOWN

lead

Alimentiv Inc.

OTHER

NCT04576000 - Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis | Biotech Hunter | Biotech Hunter